Oncolytic T-VEC virotherapy plus neoadjuvant chemotherapy in nonmetastatic triple-negative breast cancer: a phase 2 trial

Soliman, Hatem; Hogue, Deanna; Han, Hyo S.; Mooney, Blaise; Costa, Ricardo; Lee, Marie Catherine; Niell, Bethany L.; Williams, Angela; Chau, Alec; Falcon, Shannon; Soyano, Aixa; Armaghani, Avan; Khakpour, Nazanin; Weinfurtner, R. Jared; Hoover, Susan; Kiluk, John V.; Laronga, Christine; Rosa, Marilin; Khong, Hung T.; Czerniecki, Brian J.

doi:10.1038/s41591-023-02210-0

Cited by 39 publications

(29 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[35][36][37] One such OV vaccine is talimogene laherparepvec, a first-generation recombinant herpes simplex virus product. [38][39][40] Adenovirus is a different frequently utilized OV in addition to herpes simplex virus because of its versatility and simplicity of handling. The activity of tumor-infiltrating CD8 + T lymphocytes that has been suppressed by the immunosuppressive tumor microenvironment can be restored by local injection or OV-mediated production of ligands for Toll-like receptors (TLR), which increases the anticancer effect.…”

Section: Oncolytic Virus (Ov)-based Cancer Vaccinesmentioning

confidence: 99%

“…Cancer cells that have been infected with the OV release cytokines and reactive oxygen species that activate immune system cells as well as cause oncolysis 35‐37 . One such OV vaccine is talimogene laherparepvec, a first‐generation recombinant herpes simplex virus product 38‐40 . Adenovirus is a different frequently utilized OV in addition to herpes simplex virus because of its versatility and simplicity of handling.…”

Section: Cancer Vaccine Platform Typesmentioning

confidence: 99%

See 1 more Smart Citation

Recent advances in mRNA‐based vaccine for cancer therapy; bench to bedside

Kenoosh,

Pallathadka,

Hjazi

et al. 2024

Cell Biochemistry & Function

View full text Add to dashboard Cite

The messenger RNA (mRNA) vaccines have progressed from a theoretical concept to a clinical reality over the last few decades. Compared to conventional vaccination methods, these vaccines have a number of benefits, such as substantial potency, rapid growth, inexpensive production, and safe administration. Nevertheless, their usefulness was restricted up to now due to worries about the erratic and ineffective circulation of mRNA in vivo. Thankfully, these worries have largely been allayed by recent technological developments, which have led to the creation of multiple mRNA vaccination platforms for cancer and viral infections. The mRNA vaccines have been demonstrated as a powerful alternative to traditional conventional vaccines because of their high potency, safety and efficacy, capacity for rapid clinical development, and potential for rapid, low‐cost manufacturing. The paper will examine the present status of mRNA vaccine technology and suggest future paths for the advancement and application of this exciting vaccine platform as a common therapeutic choice.

show abstract

Section: Oncolytic Virus (Ov)-based Cancer Vaccinesmentioning

confidence: 99%

Section: Cancer Vaccine Platform Typesmentioning

confidence: 99%

Recent advances in mRNA‐based vaccine for cancer therapy; bench to bedside

Kenoosh,

Pallathadka,

Hjazi

et al. 2024

Cell Biochemistry & Function

View full text Add to dashboard Cite

show abstract

“…OV could be effective in combination with chemotherapy when delivered to TNBC tumors as a neoadjuvant therapy. In a phase II trial with 37 patients, 45.9% of patients demonstrated a response, 89% remained disease-free two years post-therapy, and no disease relapse was detected in patients showing a potential response to OV-based combination therapy [ 172 ].…”

Section: Potential Applications Of Precision-medicine Therapy For Tnbcmentioning

confidence: 99%

Recent Advances with Precision Medicine Treatment for Breast Cancer including Triple-Negative Sub-Type

Subhan

Parveen

Shah

et al. 2023

Cancers

View full text Add to dashboard Cite

Breast cancer is a heterogeneous disease with different molecular subtypes. Breast cancer is the second leading cause of mortality in woman due to rapid metastasis and disease recurrence. Precision medicine remains an essential source to lower the off-target toxicities of chemotherapeutic agents and maximize the patient benefits. This is a crucial approach for a more effective treatment and prevention of disease. Precision-medicine methods are based on the selection of suitable biomarkers to envision the effectiveness of targeted therapy in a specific group of patients. Several druggable mutations have been identified in breast cancer patients. Current improvements in omics technologies have focused on more precise strategies for precision therapy. The development of next-generation sequencing technologies has raised hopes for precision-medicine treatment strategies in breast cancer (BC) and triple-negative breast cancer (TNBC). Targeted therapies utilizing immune checkpoint inhibitors (ICIs), epidermal growth factor receptor inhibitor (EGFRi), poly(ADP-ribose) polymerase inhibitor (PARPi), antibody–drug conjugates (ADCs), oncolytic viruses (OVs), glucose transporter-1 inhibitor (GLUT1i), and targeting signaling pathways are potential treatment approaches for BC and TNBC. This review emphasizes the recent progress made with the precision-medicine therapy of metastatic breast cancer and TNBC.

show abstract

“…In a different phase II study with T-vec, it was administered IT and combined with paclitaxel, followed by doxorubicin, cyclophosphamide, and surgery in patients with stage 2–3 TNBC. This study has been completed, with an analysis having been carried out of 37 of the 40 enrolled patients’ biopsies and trial outcome results (NCT02779855) [ 168 ]. The primary end point of the trial was met as 45.9% of patients having a grade 0 residual cancer burden index (RCB) and the RCB0-1 (minimal residual disease) rate being 65%, totaling 24 of 37 analyzed patients.…”

Section: Ovs In the Clinical Stage For Tnbcmentioning

confidence: 99%

Triple-Negative Breast Cancer: Basic Biology and Immuno-Oncolytic Viruses

Monaco

Idris

Essani

2023

Cancers

View full text Add to dashboard Cite

Triple-negative breast cancer (TNBC) is the most lethal subtype of breast cancer. TNBC diagnoses account for approximately one-fifth of all breast cancer cases globally. The lack of receptors for estrogen, progesterone, and human epidermal growth factor 2 (HER-2, CD340) results in a lack of available molecular-based therapeutics. This increases the difficulty of treatment and leaves more traditional as well as toxic therapies as the only available standards of care in many cases. Recurrence is an additional serious problem, contributing substantially to its higher mortality rate as compared to other breast cancers. Tumor heterogeneity also poses a large obstacle to treatment approaches. No driver of tumor development has been identified for TNBC, and large variations in mutational burden between tumors have been described previously. Here, we describe the biology of six different subtypes of TNBC, based on differential gene expression. Subtype differences can have a large impact on metastatic potential and resistance to treatment. Emerging antibody-based therapeutics, such as immune checkpoint inhibitors, have available targets for small subsets of TNBC patients, leading to partial responses and relatively low overall efficacy. Immuno-oncolytic viruses (OVs) have recently become significant in the pursuit of effective treatments for TNBC. OVs generally share the ability to ignore the heterogeneous nature of TNBC cells and allow infection throughout a treated tumor. Recent genetic engineering has allowed for the enhancement of efficacy against certain tumor types while avoiding the most common side effects in non-cancerous tissues. In this review, TNBC is described in order to address the challenges it presents to potential treatments. The OVs currently described preclinically and in various stages of clinical trials are also summarized, as are their strategies to enhance therapeutic potential.

show abstract

Oncolytic T-VEC virotherapy plus neoadjuvant chemotherapy in nonmetastatic triple-negative breast cancer: a phase 2 trial

Cited by 39 publications

References 26 publications

Recent advances in mRNA‐based vaccine for cancer therapy; bench to bedside

Recent advances in mRNA‐based vaccine for cancer therapy; bench to bedside

Recent Advances with Precision Medicine Treatment for Breast Cancer including Triple-Negative Sub-Type

Triple-Negative Breast Cancer: Basic Biology and Immuno-Oncolytic Viruses

Contact Info

Product

Resources

About